Class of 2024
For unparalleled research discoveries that have defined the genetic and epigenetic control mechanisms governing T-cell exhaustion, and for elucidating the molecular mechanisms underlying PDL-1 blockade, resulting in the clinical development of various immunotherapies, including several FDA-approved immune checkpoint inhibitor therapies for multiple cancer indications.
*Full-length biography pending